In this section
This information is intended to provide a framework for clinicians
prescribing blood products for children at The Royal Children’s Hospital (RCH).
Please refer to the Blood Transfusion – Fresh Blood Products Procedure and the Consent – Informed Procedure
Patient consent to blood product form MR 634/A (RCH use only)
Blood products have the potential to save lives, and frequently provide
considerable benefit to patients when used appropriately. There are significant
risks associated with transfusion and the decision to transfuse a patient
should be a carefully considered decision and involve a discussion with the
patient/parent, with an opportunity for the patient/parent to ask any
The following should be part of the consent discussion:
Some alternatives or processes that may decrease the need for
transfusion in specific circumstances are:
Information on blood product transfusion will be offered to the
patient/parents and this will be documented on the Patient consent to blood products MR634/A
RCH Kids health
info on Blood product transfusion and Intravenous immunoglobulin (IVIG) infusion.
The Australian Red Cross Blood Service has transfusion information for parents and children. This includes information in languages other than English.
They also provide specific Neonatal
transfusion information and transfusion fact sheets
Department of Health Blood Matters program blood transfusion information in language other than English
The RCH has a
specific consent form for the transfusion of blood products; Patient consent to blood products MR634/A. Document the consent for the transfusion of blood and blood products on this form. The RCH surgical consent form does not include blood product transfusion
consent. If there is a reasonable expectation that a blood product transfusion may be required during a surgical
procedure (i.e. a blood group and antibody screen is ordered) the MR634/A consent form should be completed with the patient/family prior to surgery.
The provision of information to the patient/family must be documented on the MR634/A form.
Consent for blood product transfusion remains paper based at the RCH. A copy of the blood product transfusion consent should be kept in the patient’s bedside folder until they are discharged. The
original signed form should be sent to HIS for scanning.
Once the blood product transfusion consent form has been scanned into EMR, or if
the patient has a long standing consent, it can be viewed in chart review
section of EMR under the Media tab. Clinicians must sight the consent for
blood product transfusion on the MR634/A prior to completing the “prepare”
and “transfuse” order in EMR. If this has not been obtained the transfusion
will be delayed until consent is obtained. The only exception is a critical
bleeding event where consent should be sought retrospectively.
Blood product transfusion consent is valid
for the entire current admission, for example is the patient requires multiple blood product transfusion during the admission only one blood product transfusion consent form is required.
When a patient needs ongoing transfusion support, consent can be valid for 12 months. The consent form should indicate the expiry date of
long term consent.
the patient/parent/guardian does not wish to receive a blood product
transfusion see Blood Refusal – Management of Procedure and document this in both the medical record and on the blood
transfusion consent form. The FYI flag of the EMR patient should
also be completed. The FYI flag will stay valid for
the entirety of the patient’s lifetime, across multiple admissions unless it is
deactivated due to change of mind or circumstance.